Sarah L. Clark

Bags versus flasks: a comparison of cell culture systems for the production of dendritic cell-based immunotherapies: CANCER IMMUNOTHERAPY CULTURE VESSELS

In recent years, cell‐based therapies targeting the immune system have emerged as promising strategies for cancer treatment. This review summarizes manufacturing challenges related to production of antigen presenting cells as a patient‐tailored cancer therapy. Understanding cell‐material interactions is essential because in vitro cell culture manipulations to obtain mature antigen‐producing cells can significantly alter their in vivo performance. Traditional antigen‐producing cell culture protocols often rely on cell adhesion to surface‐treated hydrophilic polystyrene flasks. More recent commercial and investigational cancer immunotherapy products were manufactured using suspension cell culture in closed hydrophobic fluoropolymer bags. The shift to closed cell culture systems can decrease risks of contamination by individual operators, as well as facilitate scale‐up and automation. Selecting closed cell culture bags over traditional open culture systems entails different handling procedures and processing controls, which can affect product quality. Changes in culture vessels also entail changes in vessel materials and geometry, which may alter the cell microenvironment and resulting cell fate decisions. Strategically designed culture systems will pave the way for the generation of more sophisticated and highly potent cell‐based cancer vaccines. As an increasing number of cell‐based therapies enter the clinic, the selection of appropriate cell culture vessels and materials becomes a critical consideration that can impact the therapeutic efficacy of the product, and hence clinical outcomes and patient quality of life.